Scientists create CRISPR-based drug candidate targeting the microbiome
A new drug candidate targeting E. coli in the gut is in phase 1 clinical trials. According to a new paper it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections.
from Latest Science News -- ScienceDaily https://ift.tt/qJmEtRr
from Latest Science News -- ScienceDaily https://ift.tt/qJmEtRr
Comments
Post a Comment